Hybrid Molecules of p53 Activators and Protoflavones to Target Multiple Myeloma
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500600 ↗At a glance
Journal article in ChemMedChem, 2025. Written by Francisca Lopes and 9 co-authors. Institution: Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal. Major MEDLINE topics: Multiple Myeloma, Tumor Suppressor Protein p53, Antineoplastic Agents. 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: bilateral action, Hungarian Academy of Sciences, National Science and Technology Council, Taiwan.
Abstract (original language)
Multiple myeloma is a rare blood cancer that develops from abnormal plasma cells in the bone marrow. Treatment of multiple myeloma remains an enormous challenge. In this work, hybrid compounds are developed and studied for their potential use against multiple myeloma. The compounds are designed to act by a dual mechanism of action, activation of the p53 pathway, and inhibition of the ataxia telangiectasia and Rad3‐related protein (ATR). To evaluate the selectivity for the p53 pathway, the compounds are first evaluated in an isogenic pair of HCT116 colon cancer cell lines, with and without p53, and in two breast cancer cell lines expressing different forms of p53. Then, the growth inhibitory effect of the hybrid compounds is tested against the multiple myeloma cell lines RPMI 8226 (mutant p53) and MM.1S (wild‐type p53). At the same time, compound 15 is confirmed to inhibit doxorubicin‐ but not UV‐induced DNA damage response via the ATR/Chk1 signaling pathway. The hybrids show lower IC 50 values compared to the fragments alone, highlighting the potential for using hybrid molecules containing two pharmacophores with complementary activities. These results suggest that novel hybrid molecules may serve as new leads against multiple myeloma.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal.
- Institute of Pharmacognosy, University of Szeged, Eötvös str. 6, H-6720, Szeged, Hungary.
- School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211, Genève 4, Switzerland.
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Rue Michel-Servet 1, 1211, Genève 4, Switzerland.
- LAQV/REQUIMTE, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal.
- Graduate Institute of Natural Products, Kaohsiung Medical University, Shih-Chuan first Road. 100, Kaohsiung, 807, Taiwan.
ORCID profiles: Attila Hunyadi, Maria M M Santos
Funding
- bilateral action
- Hungarian Academy of Sciences
- National Science and Technology Council, Taiwan
- Fundação para a Ciência e a Tecnologia
- COST
- NMR Network
- European Regional Development Fund
- Swiss National Science Foundation
Cite
APA
Lopes, F., Girst, G., Rincón, R., Ferreira, R. J. F., Gonçalves, L. M., Saraiva, L., Wang, H. C., Cuendet, M., Hunyadi, A., & Santos, M. M. M. (2025). Hybrid Molecules of p53 Activators and Protoflavones to Target Multiple Myeloma. ChemMedChem. https://doi.org/10.1002/cmdc.202500600
Vancouver
Lopes F, Girst G, Rincón R, Ferreira RJF, Gonçalves LM, Saraiva L, et al. Hybrid Molecules of p53 Activators and Protoflavones to Target Multiple Myeloma. ChemMedChem. 2025. doi:10.1002/cmdc.202500600
BibTeX
@article{Lopes2025,
author = {Lopes, Francisca and Girst, Gábor and Rincón, Rafael and Ferreira, Ricardo J F and Gonçalves, Lídia M and Saraiva, Lucília and Wang, Hui-Chun and Cuendet, Muriel and Hunyadi, Attila and Santos, Maria M M},
title = {Hybrid Molecules of p53 Activators and Protoflavones to Target Multiple Myeloma},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500600}
}
EUVIMED